ORIGINAL ARTICLE

β-Adrenergic Contributions to Emotion and Physiology During an Acute Psychosocial Stressor

Jennifer K. MacCormack, PhD, Emma L. Armstrong-Carter, BA, Monica M. Gaudier-Diaz, PhD,
Samantha Meltzer-Brody, MD, Erica K. Sloan, PhD,
Kristen A. Lindquist, PhD, and Keely A. Muscatell, PhD

ABSTRACT

Objective: β-Adrenergic receptor signaling, a critical mediator of sympathetic nervous system influences on physiology and behavior, has long been proposed as one contributor to subjective stress. However, prior findings are surprisingly mixed about whether β-blockade (e.g., propranolol) blunts subjective stress, with many studies reporting no effects. We reevaluated this question in the context of an acute psychosocial stressor with more comprehensive measures and a larger-than-typical sample. We also examined the effects of β-blockade on psychophysiological indicators of sympathetic and parasympathetic nervous system reactivity, given that β-blockade effects for these measures specifically under acute psychosocial stress are not yet well established.

Methods: In a double-blind, randomized, placebo-controlled study, 90 healthy young adults received 40 mg of the β-blocker propranolol or placebo. Participants then completed the Trier Social Stress Test, which involved completing an impromptu speech and difficult arithmetic in front of evaluative judges. Self-reported emotions and appraisals as well as psychophysiology were assessed throughout.

Results: Propranolol blunted Trier Social Stress Test preejection period reactivity ($b = 9.68$, $p = .003$), a marker of sympathetic nervous system activity, as well as salivary α-amylase reactivity ($b = -0.50$, $p = .006$). Critically, propranolol also blunted negative, high arousal emotions in response to the stressor ($b = -0.22$, $p = .026$), but cognitive appraisals remained intact (b values < -0.17, p values $> .10$).

Conclusions: These results provide updated experimental evidence that β-adrenergic blockade attenuates negative, high arousal emotions in response to a psychosocial stressor while also blunting sympathetic nervous system reactivity. Together, these findings shed light on the neurophysiological mechanisms by which stressors transform into the subjective experience we call "stress."

Trial Registration: ClinicalTrials.gov Identifier: NCT02972554.

Key words: emotion, appraisals, stress, β-blockade, propranolol, psychophysiology.

INTRODUCTION

Psychological stressors have long been appreciated as determinants of physical health, emotional well-being, and social behavior (1–5). Importantly, subjective stress—the affective feelings and appraisals that individuals experience in the face of a stressor—is sometimes more predictive of health and well-being than "objective" measures such as cardiovascular or neuroendocrine markers (5–8). Despite the predictive utility of subjective stress, we know surprisingly little about how subjective stress is generated in the first place. Some work has tested potential neurophysiological contributions to subjective stress in humans by administering β-blockers such as *propranolol*, which block β-adrenergic receptors, a critical signaling pathway for epinephrine and norepinephrine (9,10). This study aimed to provide a more complete understanding of the effects of β-blockade on the acute stress experience while also shedding light on long-standing questions about the nature of human emotion.

Current neuroscientific perspectives argue that the brain's core function is *allostasis*, the process of monitoring, managing, and coordinating physiology to support an organism's movement, growth, reproduction, and behavior (11,12). Two closely interworking systems by which the brain may in part enact allostasis are the sympathetic nervous system (SNS) and adrenergic/noradrenergic systems. These systems are known to support arousal and the mobilization of neurophysiological resources underpinning alertness, saliency, and behavioral coping (13–15). In particular, the catecholamines epinephrine and norepinephrine

---

BMI = body mass index, **BP** = blood pressure, **HPA axis** = hypothalamic-pituitary-adrenal axis, **HR** = heart rate, **ICG** = impedance cardiography, **PEP** = preejection period, **PNS** = parasympathetic nervous system, **RSA** = respiratory sinus arrhythmia, **sAA** = salivary α-amylase, **SNS** = sympathetic nervous system, **TSST** = Trier Social Stress Test

---

SDC Supplemental Digital Content

are released by the medulla in the adrenal glands and by the ends of sympathetic nerve fibers, serving as the primary neurotransmitters that convey SNS signaling to peripheral organs (16). Epinephrine and norepinephrine subsequently act by binding to α- and β-adrenergic receptors, found widely across the body and brain (17,18).

β-Adrenergic receptor signaling has long been implicated in the generation of affect (e.g., feeling tense, stressed, anxious), given its role in conveying epinephrine- and norepinephrine-mediated SNS signals to peripheral organs. The idea that peripheral signals contribute to affect is consistent with early theories of emotion (19,20) as well as current theories arguing that both the body's physiological states and interoception of those states help generate *affect*, or feelings of valence (pleasure versus displeasure) and arousal (activation versus quiescence; (21,22)). To test these ideas, past research has examined the effects of β-blocker administration on affect, acute stress, and/or mood disorder symptoms, with propranolol being the most widely used. Propranolol is a highly lipophilic, nonselective β-blocker, meaning that it can cross the blood-brain barrier easily and blocks the binding of epinephrine and norepinephrine across all types of β-adrenergic receptors. In treatment, it has been mostly used to reduce hypertension, tachycardia, and muscle tremors but is sometimes prescribed off-label to reduce anxiety in acutely stressful situations such as musical performances or public speaking (9). Despite this off-label use, a long history of experimental evidence remains equivocal about the effects of propranolol (and other types of β-blockers) on subjective ratings of anxiety, stress, and affect (23–50).

Mixed findings may be due to several limitations of prior research. First, most studies are likely underpowered. Specifically, the effect size for propranolol on affect is probably small, yet propranolol groups in most studies are *n* < 20 (Table S1, Supplemental Digital Content [SDC], http://links.lww.com/PSYMED/A784). Furthermore, emotion, affect, or subjective stress is inconsistently measured. Studies tend to focus on a narrow subset of feelings (e.g., state anxiety, single-item stress ratings), suggesting that null effects could be driven by impoverished measurement. Indeed, people tend to report a range of feelings during stressors in addition to anxiety and fear, including anger, embarrassment, and shame (51), yet these other emotions have remained largely ignored in past β-blockade work. Effects are further complicated by some studies examining drug effects on affect only at rest and other studies examining drug effects only in reaction to a stimulus (e.g., stressor). To address these ambiguities, we assessed the effects of propranolol on a variety of emotional states, ranging in valence and arousal, both at rest (pre/post drug) and with respect to acute stressor reactivity (pre/post stressor). Lastly, although appraisals are another oft-measured dimension of subjective stress (52), to our knowledge, there are no published findings on the effects of propranolol on stress appraisals. Thus, we aimed to provide initial evidence clarifying the effects of β-blockade on appraisals.

Given that stressors also impact physiology and health, it is critical to examine *both* subjective and physiological changes in parallel. Consequently, we assessed the extent to which β-blockade impacts autonomic and neuroendocrine markers of the SNS, parasympathetic nervous system (PNS), and hypothalamic-pituitary-adrenal (HPA) axis, which are known to shift during acute stressors. This allowed us to disambiguate specific effects of β-blockade on the reactivity of several physiological systems implicated in stress. As our primary SNS indicator, we measured preejection period (PEP),

a cardiovascular measure of sympathetic influence on the cardiac cycle. We also measured salivary α-amylase (sAA), given that it may in part reflect SNS activity (53,54). Although classic work shows that β-blockade lengthens PEP at rest, during physical exercise, and under cognitive load (55–58), there is little work examining the effects of β-blockade on PEP *under psychosocial stress* (i.e., the Trier Social Stress Test, or TSST; 59,60), with most work instead focusing on blood pressure (BP) and heart rate (HR) or neuroendocrine measures such as sAA and cortisol (26,36,37,41,61,62). We additionally tested the specificity of β-blockade on SNS versus PNS reactivity (59) by assessing respiratory sinus arrhythmia (RSA), a marker of parasympathetic cardiac influence. Finally, we built on prior work examining effects of β-blockade on HPA-axis markers such as cortisol (37,61), to clarify whether past null effects are replicable while further confirming that the effects of β-blockade are SNS specific.

To test the aforementioned hypotheses and gaps in the literature, we used a preregistered, double-blind, randomized, placebo-controlled design and manipulated β-adrenergic signaling via administration of a single 40-mg dose of propranolol (*n* = 43) versus placebo (*n* = 47) before the TSST (63). Drawing on diverse tools from psychopharmacology, psychophysiology, and affective science, we used comprehensive, repeated measures of emotions, appraisals, autonomic psychophysiology, and salivary markers in a sample size that more than doubles that of most prior studies. We hypothesized that TSST exposure would result in increased unpleasant, high arousal emotions (e.g., anxiety, anger), and that pretreatment with propranolol would blunt the intensity of these feelings. To determine specificity, we also examined negative, low arousal emotions (e.g., *boredom*); positive, high arousal emotions (e.g., *excitement*); and positive, low arousal emotions (e.g., *contentment*). We further explored the effects of β-blockade on TSST appraisals, clarifying whether β-adrenergic signaling contributes to affect only or if it also influences how people evaluate stressors. Although we hypothesized that β-blockade should alter affect, it was less clear whether β-blockade would alter appraisals given the lack of prior research in this area. One possibility is that appraisals may be less sensitive to in-the-moment neurophysiological fluctuations relative to affect, as appraisals may draw more upon schemas about the situational features of stressors (52,64). Finally, we predicted that propranolol would blunt SNS reactivity but sought to contrast this specificity against PNS and HPA reactivity.

METHODS

Participants

Ninety healthy young adults (44% female; 56.7% White; mean age = 20.29 ± 1.46 years, 18–25 years; mean body mass index [BMI] = 22.78 ± 2.47 kg/m², 18.5–28.9 kg/m²; Table 1) were recruited from the University of North Carolina at Chapel Hill and its surrounding community via flyers, class announcements, and listservs. Eligibility was assessed via telephone interviews. Individuals were excluded if they reported prior use of β-blockers, a history of mental or physical health problems, regular nicotine or recreational drug use, prescription medication use, pacemaker or cardiac irregularities, BMI greater than 33 kg/m², or resting HR/BP below propranolol safety guidelines (<60 beats/min, 80 mm Hg). Participants were instructed to come to the laboratory well hydrated, having eaten a normal meal, and refraining from caffeine, high sugar, or exercise that day. On the session day, participants had to report good health and no use of over-the-counter medications, and must exhibit a

TABLE 1. Sample Characteristics Compared by Condition

Demographics	Placebo	Propranolol	Total	p
Sex, n (%)				
Female	21 (23.3)	19 (21.1)	40 (44.4)	.962[a]
Male	26 (28.9)	24 (26.7)	50 (55.6)	
Race, n (%)				
Asian descent	12 (13.3)	11 (12.2)	23 (25.6)	.876[a]
African descent	5 (5.6)	3 (3.3)	8 (8.8)	
European descent	27 (30.0)	24 (26.7)	51 (56.7)	
Biracial or multiracial	2 (2.2)	4 (4.4)	6 (6.7)	
Other	1 (1.1)	1 (1.1)	2 (2.2)	
Age, mean (SD), y	20.49 (1.56)	20.07 (1.28)	20.29 (1.46)	.173[b]
BMI, mean (SD), kg/m²	23.09 (2.43)	22.44 (2.50)	22.78 (2.47)	.220[b]
Objective SES, mean (SD)	16.52 (1.93)	16.19 (1.89)	16.36 (1.91)	.408[b]

SD = standard deviation; BMI =body mass index; SES = socioeconomic status.

Frequency counts show percentages of total sample. Objective SES was operationalized as the mean years of education that both parents completed.

[a] Difference tested with Pearson χ^2.

[b] Difference tested with independent-samples *t* tests.

resting HR/BP within the safety cutoff range. Hereinafter we describe procedures and measures, but see SDC (http://links.lww.com/PSYMED/A784) for further details and CONSORT diagram.

Procedure

The study was preregistered with ClinicalTrials.gov (Trial ID: NCT02972554) and approved by the university's institutional review board. After informed written consent, all participants completed the study from 12 to 5 PM, with procedures time-matched to control for diurnal effects (e.g., cortisol). See Figure 1 for timeline. Each participant was randomly assigned to receive either a single 40-mg dose of propranolol or placebo, self-administered orally under supervision. We chose a 40-mg dose given that this is both a common dosage used in prior studies with healthy adults (27,36,39) and given that this is a common dosage for one-time performance anxiety situations. Drug randomization was completed and provided in identical capsules by the university's Investigational Drug Services Pharmacy. Staff and

participants were blind to condition, except the study physician (S.M.-B.), who remained on call for participant safety but did not interact with participants or researchers. Importantly, all participants remained in their originally assigned conditions, and there were no changes to study design, selection and exclusion criteria, or procedures.

Participants completed the TSST during the 1 to 2 hours after oral administration of propranolol, when propranolol effects are strongest (65). Participants had 2 minutes to prepare a speech about their dream job, then gave that speech for 10 minutes in front of a panel of neutral evaluative judges, whereafter they completed 5 minutes of impromptu verbal arithmetic (serial subtraction). Participants rated their emotions at baseline before drug administration (predrug baseline, or BL1), 60 minutes after drug administration (postdrug baseline, or BL2), immediately after TSST speech preparation, and immediately after the full TSST ended. Appraisals were assessed at TSST prep and post-TSST. We measured autonomic changes continuously across six epochs: 5-min BL1, 5-min BL2, 2-min TSST prep, 10-min TSST speech, 5-min TSST arithmetic task, and 7-min recovery post-TSST. Finally, participants provided passive drool saliva samples at BL1, BL2, and plus 15 and 30 minutes after TSST completion (T15 and T30). Blood samples for inflammatory markers were also collected, but results are published elsewhere (66). See also other work examining separate, secondary questions with this data (67). All participants were debriefed, paid (US$100), and discharged once physiological vitals returned to baseline.

Measures

Self-Reported Emotions

We used an expanded 40-item version of the Positive and Negative Affect Schedule (68). Participants rated how intensely they were experiencing each emotion on a Likert scale from 1 (*not at all*) to 5 (*extremely*). Following prior standardizations (69,70), mean scores covered the four quadrants of negative, high arousal (e.g., *stressed*); negative, low arousal (e.g., *bored*); positive, high arousal (e.g., *excited*); and positive, low arousal (e.g., *relaxed*). See SDC (http://links.lww.com/PSYMED/A784) for all items.

Self-Reported Appraisals

We focused on *challenge* and *threat appraisals*, thought to occur when an individual perceives a situation to be challenging but manageable versus threatening without sufficient coping resources (71,72). Challenge-threat appraisals were collected immediately after TSST prep and post-TSST, with six items for challenge appraisals (e.g., "I have the abilities to perform the upcoming task successfully") and six items for threat appraisals (e.g., "The previous task was very demanding") on a Likert scale from 1 (*strongly disagree*) to 7 (*strongly agree*). As a third, more diverse appraisal measure, we assessed participants' negative evaluations of the self and the stressful

FIGURE 1. Study timeline illustrating repeated measure timing of self-reported emotions, continuous ECG and ICG, and salivary cortisol and α-amylase measures. Note that, although not depicted here, appraisals were measured alongside emotion, but only at the TSST prep and post-TSST time points. ECG = electrocardiogram; ICG = impedance cardiography; TSST = Trier Social Stress Test; sAA = salivary α-amylase.

situation. This negative appraisal measure presented 25 negative descriptors capturing evaluations of personal responsibility for performance (internal attributions or self-evaluations, e.g., blame, incompetence, failure) versus appraisals about the situation's controllability and unexpectedness (external attributions or evaluations of the experimenters and situation, e.g., unfair, wronged), on a Likert scale from 1 (*not at all*) to 6 (*extremely*). Finally, as a more direct measure of participants' evaluations of the TSST itself, participants rated on six items how difficult, stressful, and enjoyable they found the speech and math tasks (e.g., "The math task was difficult") on a Likert scale from 1 (*not at all*) to 6 (*extremely*). As the negative appraisals and TSST task ratings queried how participants perceived how the TSST went, these were only administered post-TSST. See SDC (http://links. lww.com/PSYMED/A784) for further details.

Autonomic Psychophysiology

To assess sympathetic and parasympathetic activity, we collected continuous electrocardiography and impedance cardiography (ICG) at a sampling rate of 1000 Hz using Mindware Technologies (Gahanna, Ohio). Data for analyses were drawn from the last minute of each baseline, the first minute from each stress phase (preparation, speech, arithmetic), and the last minute of recovery. PEP, a marker of SNS-specific influence on the heart (73), captures the length of time (in milliseconds) between the onset of depolarization and the start of left ventricular contraction. Shorter (smaller) PEP values suggest faster periods of cardiac contractility via SNS signaling. RSA is characterized as heart rate variability synchronized with the respiratory cycle, wherein the R-to-R interval (the length of time between heartbeats) is shorter (faster) during inhalation and longer (slower) during exhalation. Prior studies suggest that RSA reflects parasympathetic influence of the vagus nerve on the heart (74). Higher RSA values suggest less withdrawal of the PNS. In addition to PEP and RSA, we extracted mean HR (in beats per minute) given its prevalence in past research on β-blockade and stress. However, HR is a general measure that incorporates both SNS and PNS contributions; as such, we do not focus on HR in the main text (see SDC, http://links.lww.com/PSYMED/A784). HR was used as a covariate in models with RSA, given recent recommendations (75). Finally, respiration was estimated from ICG to parse apart respiration from RSA but was not otherwise analyzed. See SDC (http://links.lww.com/PSYMED/A784) for further discussion of electrocardiography/ICG measurement, scoring, and reliability.

Salivary Measures

Saliva samples were frozen and stored at −80°C until analysis. Salivary concentrations were assessed using commercially available chemiluminescence immunoassay with high sensitivity (IBL International, Hamburg, Germany) following the manufacturer's instructions. Cortisol was analyzed in duplicate, and sAA in singlet. The interassay and intra-assay coefficients of variation for cortisol were both <8%; the interassay coefficient of variation for sAA was <6%.

Covariates

Participants self-reported weight and height, from which BMI was calculated and included in all models (76). Additional covariates were sex and socioeconomic status (operationalized as mean years of parental education), given work showing that both alter stress reactivity (77). For salivary models, we adjusted for the menstrual cycle (menstrual, follicular, ovulation, or luteal phases estimated from participants' reported first day of their last period and cycle length), given work showing that stage of menstrual cycle alters HPA reactivity (78).

Statistical Analyses

Cortisol and sAA were log transformed, given their right-skewed distribution. We also examined and excluded outliers that were ±3 standard deviations (SDs) from the mean on any measure within each time point within each condition; there were only a few such outliers with most time points

across measures having no outliers. All data were analyzed in R using the *lme4* package (79). As time points are nested within individuals, we used multilevel modeling with the inclusion of a random intercept to model individual differences in each outcome. For analyses, drug was coded 0 = placebo, 1 = propranolol, and consistent with other psychology studies, sex was coded 0 = female, 1 = male. In addition, we aggregated across the TSST speech and math tasks for our index of reactivity during the active stressor but examined TSST prep as its own time point, as it likely reflects anticipatory stress. We conducted analyses both with respect to the predrug baseline (BL1) and postdrug baseline (BL2) as these test different questions. Analyses with respect to BL1 serve as a manipulation check while also testing the effects of propranolol on our outcomes of interest during a neutral resting state (from predrug to postdrug baselines). Analyses with respect to BL2 provide a purer test of how propranolol, once in effect, alters reactivity to the stressor. Throughout the main text, we report most results with respect to BL2, given that this is the strongest test of drug effects on reactivity. In a few cases, we also report manipulation checks comparing BL1 to BL2 but are here careful to specify which baseline is being discussed. See SDC (http://links.lww.com/PSYMED/A784) for BL1 results.

RESULTS

Multilevel models were used to assess the main effects of *time point* (i.e., baseline and task effects), main effects of *drug*, and *time point by drug* interactions on emotion and appraisal reports, sympathetic reactivity (i.e., PEP), parasympathetic reactivity (i.e., RSA), sAA reactivity, and HPA-axis reactivity (i.e., cortisol). Conditions were matched on sex, age, and race/ethnicity (Table 1) and did not differ on depressive or anxiety symptoms, recent perceived life stress, fear of evaluation (SDC Table S2, http://links.lww.com/PSYMED/A784), BMI, or socioeconomic status. Unstandardized coefficients are presented throughout the Results section, but confidence intervals and standardized β values are presented in tables, with β values serving as effect size estimates.

Effects on Subjective Stress

Affect

As predicted, we found a main effect of time point on negative, high arousal emotions (Figure 2, Table 2), such that these emotions were more intense after both the speech prep (anticipatory stress; $b = 0.38$, SE = 0.07, $p < .0001$) and immediately after the TSST ($b = 0.75$, SE = 0.07, $p < .0001$) relative to the postdrug baseline. During speech prep, the interaction between drug by time point was nonsignificant ($b = -0.18$, SE = 0.10, $p = .068$), but immediately after the TSST, those on propranolol reported lower negative, high arousal emotions relative to those on placebo ($b = -0.22$, SE = 0.10, $p = .026$). Interestingly, there was no main effect of drug on negative, high arousal emotions from the predrug to postdrug baseline when participants were at rest. Specifically, there was no difference in negative, high arousal emotions between propranolol versus placebo at the postdrug baseline ($b = -0.03$, SE = 0.08, $p = .742$ in Table 2), nor was there a significant interaction of drug by postdrug baseline relative to the predrug baseline ($b = 0.02$, SE = 0.09, $p = .837$ in SDC Table S2, http://links.lww.com/PSYMED/A784), suggesting that propranolol administration did not alter negative, high arousal emotions during a neutral, resting state. As a secondary question, we examined whether propranolol impacted other emotions besides negative, high arousal states. There were significant TSST time point main effects on other affective quadrants (e.g.,

FIGURE 2. Placebo versus propranolol effects across time on (A) negative, high arousal emotions, (B) PEP, and (C) sAA. Marginal means and standard errors depicted, but see Tables 2 and 4 for significant effects. Note that *lower* PEP represents shorter (faster) periods of cardiac contractility, consistent with greater SNS activity. PEP = preejection period; sAA = salivary α-amylase; TSST = Trier Social Stress Test.

decreased positive, low arousal emotions), but drug by TSST effects were specific to negative, high arousal emotions (Table 2).

Appraisals

As would be expected with the TSST, challenge appraisals decreased from speech prep to post-TSST ($b = -0.55$, SE = 0.12, $p < .0001$); negative appraisals also increased over time ($b = 0.38$, SE = 0.07, $p < .0001$; Table 3). There was no significant change in threat appraisals from speech prep to post-TSST ($b = 0.04$, SE = 0.12, $p = .754$). Interestingly, β-blockade did not alter appraisals on any measure, nor were any drug by time point interactions significant (all b values <−0.30–0.17, p values > .10). In addition to challenge/threat and negative appraisals, an independent t test revealed no differences in how individuals on propranolol (mean [SD] = 3.90 [0.87]) versus placebo (mean [SD] = 3.91[0.79]) judged the TSST as being difficult, stressful, or unenjoyable ($t(88) = 0.07$, $p = .943$).

Effects on Physiology

As expected, PEP was shorter (faster) during both the anticipatory stress (prep) and social evaluative (speech, math) TSST phases relative to the postdrug baseline (b values = −10.75, −10.69; SEs = 2.23, 2.21; p values < .0001; Figure 2, Table 4). Critically, propranolol altered PEP both at the postdrug baseline ($b = 9.37$, SE = 3.14, $p = .003$) and throughout the TSST speech and math tasks ($b = 9.68$, SE = 3.24, $p = .003$). Individuals on propranolol showed significantly longer PEP both at rest postdrug (BL2) and during the TSST, relative to placebo, indicating less SNS reactivity among those on propranolol. β-Blockade did not significantly alter PEP during TSST prep or poststressor recovery relative to the postdrug baseline (respectively, b values = 5.21, 2.16; p values > .10). We also examined drug and time point effects on sAA, a salivary measure under both SNS and PNS control. There were no effects of drug or time point (respectively, b values = −0.25, 0.20; p values > .10), but there was an interaction of drug by time point ($b = -0.50$, SE = 0.18, $p = .006$), such that those on propranolol showed blunted sAA reactivity at 15 minutes post-TSST compared with the postdrug baseline, relative to placebo. Interestingly, there were no effects of drug or interaction of drug by time point on RSA (when adjusting for HR; see SDC for unadjusted effects, http://links.lww.com/

PSYMED/A784). Similarly, there were no drug or drug by time point effects on cortisol reactivity, although we replicated the well-established TSST elicitation of increased cortisol. See Table 4 and SDC (http://links.lww.com/PSYMED/A784) for more on RSA and cortisol.

DISCUSSION

We demonstrated that pretreatment with propranolol altered affective experiences but not appraisals during an acute psychosocial stressor. Specifically, individuals on β-blockade reported lower negative, high arousal emotions while also exhibiting lower SNS reactivity in response to the stressor, relative to those on placebo. Although consistent with some prior work wherein propranolol blunted anxiety (27,31,38,42,43,46,48,50), the present findings contrast with several studies that did not find blunting of subjective stress (25,26,36,37,40,41,44,45,47,80). These inconsistencies in prior work may be due in part to small sample sizes and narrow measures of subjective stress—issues we sought to address herein. Moreover, the present findings reveal both psychological and physiological specificity in the effects of β-blockade. β-Blockade blunted negative, high arousal emotions, PEP, and sAA, but not low arousal emotions, positive emotions, appraisals, or measures of the PNS or HPA axis (RSA, cortisol). Together, these findings affirm that β-adrenergic signaling supports SNS-specific physiological responses while also helping transform a potentially stressful situation into the subjective experience we call "stress."

The experimental design and specificity of findings yield intriguing insights about the nature of emotion and stress. First, these findings may provide tentative evidence for the Jamesian and constructionist hypothesis that the peripheral body can contribute to affect (19–22). Although propranolol crosses the blood-brain barrier and acts on both the peripheral and central nervous systems, ongoing work with β-blockers that have peripheral-predominant effects are informative. For example, *atenolol* is a hydrophilic β-blocker that cannot easily cross the blood-brain barrier and is selective to β₁-receptors, which predominate in the heart (81). Both older and recent studies suggest that atenolol can exert anxiolytic and arousal-blunting effects (46,81,82), indicating that SNS and related signaling via peripheral β-adrenergic receptors may influence affect. As such, one possibility of the present findings is that

TABLE 2. Multilevel Fixed Effects for Emotion Reports Across Drug, Time Point, and Drug by Time Point

Predictors	b	β	SE	p	Lower 95% CI	Upper 95% CI
Mean negative, high arousal emotions						
Intercept	**1.19**	**0.01**	**0.283**	**<.001**	**0.64**	**1.75**
Drug	−0.03	−0.17	0.084	.742	−0.19	0.14
TSST prep	**0.38**	**0.28**	**0.068**	**<.001**	**0.24**	**0.51**
Post-TSST	**0.75**	**0.63**	**0.068**	**<.001**	**0.61**	**0.88**
Drug by TSST prep	−0.18	−0.09	0.099	.068	−0.38	0.01
Drug by post-TSST	**−0.22**	**−0.11**	**0.099**	**.026**	**−0.42**	**−0.03**
Sex	0.10	0.11	0.063	.104	−0.02	0.23
BMI	−0.01	−0.00	0.023	.975	−0.05	0.04
SES	−0.01	−0.04	0.017	.530	−0.04	0.02
Mean negative, low arousal emotions						
Intercept	**0.94**	**0.01**	**0.187**	**<.001**	**0.57**	**1.31**
Drug	0.08	0.13	0.053	.129	−0.02	0.19
TSST prep	−0.06	−0.12	0.040	.166	−0.14	0.02
Post-TSST	0.01	−0.00	0.040	.777	−0.07	0.09
Drug by TSST prep	−0.02	−0.02	0.058	.718	−0.14	0.09
Drug by post-TSST	−0.03	−0.03	0.058	.653	−0.14	0.09
Sex	0.02	0.04	0.042	.642	−0.06	0.10
BMI	0.01	0.04	0.015	.666	−0.02	0.04
SES	0.01	0.09	0.011	.266	−0.01	0.03
Mean positive, high arousal emotions						
Intercept	**1.81**	**0.00**	**0.584**	**.003**	**0.66**	**2.96**
Drug	0.06	0.01	0.151	.708	−0.24	0.35
TSST prep	−0.03	−0.03	0.091	.710	−0.21	0.15
Post-TSST	0.07	0.00	0.091	.465	−0.11	0.25
Drug by TSST prep	−0.02	−0.01	0.132	.891	−0.28	0.24
Drug by post-TSST	−0.13	−0.04	0.132	.332	−0.39	0.13
Sex	**0.27**	**0.19**	**0.131**	**.045**	**0.01**	**0.53**
BMI	−0.02	−0.04	0.047	.681	−0.11	0.07
SES	−0.01	−0.03	0.035	.721	−0.08	0.06
Mean positive, low arousal emotions						
Intercept	**2.48**	**0.00**	**0.582**	**<.001**	**1.33**	**3.63**
Drug	−0.18	−0.05	0.155	.242	−0.49	0.12
TSST prep	**−0.56**	**−0.27**	**0.102**	**<.001**	**−0.76**	**−0.36**
Post-TSST	**−0.61**	**−0.35**	**0.102**	**<.001**	**−0.81**	**−0.41**
Drug by TSST prep	0.25	0.08	0.148	.096	−0.04	0.54
Drug by post-TSST	0.09	0.03	0.148	.550	−0.20	0.38
Sex	0.14	0.09	0.131	.304	−0.12	0.39
BMI	−0.06	−0.10	0.047	.232	−0.15	0.04
SES	0.01	0.03	0.034	.740	−0.06	0.08

SE = standard error; CI = confidence interval; TSST = Trier Social Stress Test; BMI = body mass index; SES = socioeconomic status.

Significant effects ($p < .05$) are bolded. SEs are with respect to the unstandardized coefficients.

propranolol blunted affect in part via peripheral β-adrenergic receptors. However, as we did not design this study to adjudicate between peripheral and central pathways, future work is needed to test the degree to which effects on affect are mediated via peripheral versus central β-adrenergic receptors.

Another insight from the present findings is that the effects of β-blockade on affect were *context dependent*: propranolol did not alter emotions (of any type) from predrug to postdrug resting baselines, and only mattered in the stressful context. However, propranolol was physiologically active after administration, modulating SNS activity during the same postdrug baseline, as demonstrated by significantly slower PEP in the propranolol group. These results are consistent with "affect-as-information" and constructionist models in affective science (21,83), which hypothesize that physiological changes can influence psychological states particularly when those changes have relevance for the immediate

TABLE 3. Multilevel Fixed Effects for Appraisals Across Drug, Time Point, and Drug by Time Point

Predictors	b	β	SE	p	Lower 95% CI	Upper 95% CI
Mean challenge appraisals						
Intercept	**3.81**	**0.00**	**0.791**	**<.001**	**2.25**	**5.37**
Drug	0.08	0.02	0.198	.674	−0.31	0.48
Post-TSST	**−0.55**	**−0.31**	**0.120**	**<.001**	**−0.79**	**−0.32**
Drug by post-TSST	−0.10	−0.03	0.176	.574	−0.45	0.25
Sex	0.17	0.09	0.179	.351	−0.19	0.52
BMI	**−0.13**	**−0.19**	**0.064**	**.039**	**−0.26**	**−0.01**
SES	0.05	0.11	0.047	.254	−0.04	0.15
Mean threat appraisals						
Intercept	**4.99**	**0.00**	**0.887**	**<.001**	**3.24**	**6.74**
Drug	−0.30	−0.12	0.217	.172	−0.73	0.13
Post-TSST	0.04	0.05	0.117	.754	−0.20	0.27
Drug by post-TSST	0.11	0.03	0.172	.510	−0.23	0.45
Sex	−0.03	−0.01	0.201	.895	−0.42	0.37
BMI	0.09	0.12	0.072	.236	−0.06	0.23
SES	−0.06	−0.11	0.053	.275	−0.16	0.05
Mean negative appraisals						
Intercept	**2.14**	**0.03**	**0.451**	**<.001**	**1.25**	**3.03**
Drug	−0.06	−0.14	0.112	.592	−0.28	0.16
Post-TSST	**0.38**	**0.28**	**0.070**	**<.001**	**0.24**	**0.52**
Drug by post-TSST	−0.17	−0.08	0.102	.102	−0.37	0.03
Sex	0.05	0.05	0.100	.627	−0.15	0.25
BMI	−0.00	−0.01	0.036	.935	−0.07	0.07
SES	−0.04	−0.15	0.027	.116	−0.10	0.01

SE = standard error; CI = confidence interval; TSST = Trier Social Stress Test; BMI = body mass index; SES = socioeconomic status.

Significant effects ($p < .05$) are bolded. Reference category was TSST prep. SEs are with respect to the unstandardized coefficients.

situation. For instance, recent work showed that another physiological state, hunger, intensified affective perceptions and experiences, but only when individuals were in negative but not neutral or positive affective contexts (84). These findings provide converging evidence that allostatic changes across the body and brain, when made meaningful in a relevant situation, can influence the nature and intensity of affective states.

Although we found that β-blockade altered affect, it did not alter appraisals of the stressor. Long-standing work finds that appraisals and affect are often correlated (85); this was true herein (see SDC, http://links.lww.com/PSYMED/A784). Indeed, individuals who reported greater negative, high arousal emotions in response to the TSST were more likely to appraise the TSST as a negative event (i.e., they made more negative internal and external evaluations: $r = 0.79$, $p < .001$) and to interpret the TSST as less of a positive challenge ($r = −0.50$, $p < .001$) and more as a threat ($r = 0.59$, $p < .001$). Despite these associations, propranolol only blunted negative, high arousal emotions, whereas appraisals remained intact. All participants reported appraising the TSST similarly as a stressor, but only those on placebo experienced it as emotionally unpleasant and highly arousing. This may suggest that β-adrenergic signaling either selectively or more robustly impacts the generation of affective states without necessarily altering cognitive evaluations. Thus, although affect and appraisals are both dimensions of subjective stress, they likely reflect different underlying processes (e.g.,

affect may draw more upon ongoing physiology and interoception, whereas appraisals may draw more upon stable, a priori knowledge or schemas about situational features). Alternative possibilities are that β-adrenergic signaling (whether central or peripheral) may influence other appraisal dimensions than those measured herein, or there may be other neurophysiological pathways (e.g., HPA axis) not impaired by propranolol that are still influencing appraisals.

As hypothesized, we also found that propranolol blunted the SNS indicator PEP after drug administration and throughout the stressor. We replicated a similar pattern of results with sAA. Although the extent to which sAA can be used as an index of SNS activity versus a more general autonomic index remains debated (53,54), the present finding that propranolol blunted sAA reactivity replicates prior work (62) and aligns with existing interpretations that sAA is (at least in part) under SNS control. Interestingly, effects of propranolol were specific to PEP and sAA reactivity and did not extend to PNS (RSA) or HPA-axis (cortisol) markers. This specificity is consistent with evidence that β-adrenergic signaling mediates postsynaptic SNS effects, but not PNS cardiac effects (74). Although past literature has found mixed effects of β-blockade on RSA (86), recent work argues that it is important to account for HR in RSA analyses to parse out confounding SNS effects (75). Consistent with this possibility, as reported in SDC (http://links.lww.com/PSYMED/A784), we found a drug by time point effect on RSA in unadjusted models, but this effect was

TABLE 4. Multilevel Fixed Effects for Physiological Measures Across Drug, Time Point, and Drug by Time Point

Predictors	b	β	SE	p	Lower 95% CI	Upper 95% CI
Mean preejection period						
Intercept	**128.38**	**0.00**	**10.714**	**<.001**	**107.30**	**149.46**
Drug	**9.37**	**0.42**	**3.143**	**.003**	**3.19**	**15.56**
TSST prep	**−10.75**	**−0.22**	**2.230**	**<.001**	**−15.14**	**−6.36**
TSST tasks	**−10.69**	**−0.16**	**2.214**	**<.001**	**−15.05**	**−6.34**
TSST recovery	−1.62	−0.02	2.247	.471	−6.04	2.80
Drug by prep	5.21	0.07	3.277	.113	−1.23	11.66
Drug by tasks	**9.68**	**0.13**	**3.237**	**.003**	**3.31**	**16.05**
Drug by recovery	2.16	0.03	3.273	.510	−4.28	8.60
Sex	**5.64**	**0.17**	**2.477**	**.025**	**0.770**	**10.52**
BMI	0.67	0.06	0.905	.465	−1.12	2.45
SES	−0.89	−0.11	0.630	.164	−2.13	0.36
Log-transformed salivary α-amylase						
Intercept	**1.96**	**−0.00**	**0.833**	**.021**	**0.32**	**3.61**
Drug	−0.25	−0.25	0.203	.220	−0.65	0.15
Post-TSST T15 (15 min)	0.20	−0.02	0.125	.120	−0.05	0.44
Drug by T15	**−0.50**	**−0.13**	**0.176**	**.006**	**−0.85**	**−0.15**
Sex	0.06	0.03	0.230	.788	−0.39	0.52
Menses cycle	0.03	0.04	0.077	.713	−0.12	0.18
BMI	−0.08	−0.11	0.066	.258	−0.21	0.06
SES	**0.10**	**0.19**	**0.048**	**.049**	**0.00**	**0.19**
Mean respiratory sinus arrhythmia						
Intercept	**11.39**	**0.00**	**0.680**	**<.001**	10.05	12.73
Drug	−0.24	−0.12	0.194	.210	−0.63	0.14
TSST prep	0.19	0.09	0.171	.258	−0.14	0.53
TSST tasks	0.30	0.07	0.201	.131	−0.09	0.70
TSST recovery	−0.18	−0.04	0.160	.275	−0.49	0.14
Drug by prep	0.06	0.01	0.231	.792	−0.39	0.52
Drug by tasks	−0.25	−0.05	0.242	.305	−0.72	0.23
Drug by recovery	0.14	0.03	0.228	.548	−0.31	0.59
Heart rate	**−0.05**	**−0.64**	**0.005**	**<.001**	**−0.06**	**−0.04**
Sex	−0.26	−0.11	0.140	.072	−0.53	0.02
BMI	0.01	0.02	0.050	.797	−0.09	0.11
SES	−0.05	−0.10	0.036	.142	−0.13	0.02
Log-transformed salivary cortisol						
Intercept	0.66	0.00	0.647	.311	−0.61	1.93
Drug	**0.45**	**0.21**	**0.178**	**.013**	**0.10**	**0.80**
Post-TSST T15 (15 min)	**0.87**	**0.43**	**0.132**	**<.001**	**0.61**	**1.13**
Post-TSST T30 (30 min)	**0.60**	**0.28**	**0.132**	**<.001**	**0.34**	**0.86**
Drug by T15	−0.08	−0.02	0.190	.693	−0.45	0.30
Drug by T30	−0.10	−0.03	0.190	.611	−0.47	0.28
Sex	0.33	0.18	0.178	.070	−0.02	0.68
Menses cycle	0.00	−0.00	0.059	.999	−0.12	0.12
BMI	0.06	0.10	0.051	.216	−0.04	0.16
SES	−0.01	−0.01	0.037	.893	−0.08	0.07

SE = standard error; CI = confidence interval; TSST = Trier Social Stress Test; BMI = body mass index; SES = socioeconomic status.
Significant effects ($p < .05$) are bolded. SEs are with respect to the unstandardized coefficients.

nonsignificant after adjusting for HR. Finally, although cortisol significantly increased in response to the TSST, pretreatment with propranolol did not alter these effects. To date, prior studies have been equivocal about the effects of β-blockade on HPA reactivity (38,61). The present findings are in line with interpretations that cortisol, as an end-product of the HPA axis, may be less sensitive

to SNS signaling, at least in the context of acute psychosocial stress in healthy young adults.

This study has several limitations. First, we administered a single 40-mg dose of propranolol to mimic what is typically prescribed for the treatment of performance-related anxiety, but results may not generalize to chronic propranolol use or different dosages. For example, the effects herein might differ at another dosage amount (e.g., 60 or 80 mg) or frequency (e.g., across several days). Relatedly, prior null effects of β-blockade on emotion could be due in part to using other dosages, but this remains unclear given that some prior studies with null emotion effects also used a single 40-mg dose (29,36,39,45). However, one consideration is that stronger dosages (e.g., 80 mg) of β-blockade may exert more overt physiological effects, which could lead to unblinding (87), altering the ways in which participants attribute and report their emotions.

Other limitations include the fact that we only assessed effects in healthy young adults, so results should be replicated in other populations (people with mood disorders; older adults). Because we used more comprehensive measures that took longer to complete than a few items, another limitation is that participants may have shifted to a different state between responding to the first and final item in each self-report period. Future studies could reduce this possibility by focusing on negative, high arousal emotions, given our findings. Another unanswered question is the extent to which β-blockade alters cross-system interconnections during conditions of acute stress (e.g., correlations between SNS and PNS indicators). Finally, it should be noted that the pharmacological effects of propranolol on emotion cannot be isolated to the peripheral body, brain, or both. Although propranolol is a nonselective β-blockade, acting upon all types of β-adrenergic receptors (e.g., $β_1$, $β_2$), it seems to have slightly greater affinity for $β_2$-receptors (88). Given that atenolol is peripherally predominant and selective to $β_1$-receptors, future extensions could contrast propranolol and atenolol or other β-blockers (e.g., nadolol) to triangulate central versus peripheral effects and the role of β-adrenergic receptor classes in subjective stress and affect.

In sum, the present study leveraged comprehensive methods and measures from psychopharmacology, affective science, and psychophysiology to clarify the murky literature on β-blockers, emotion, and stress. We found evidence that β-adrenergic signaling does indeed causally contribute to affective experiences during an acute psychosocial stressor. Although everyone experiences challenging or difficult life events and daily stressors, growing work emphasizes that it is often *subjective* stress that is more predictive of downstream health and well-being (6–8). As such, understanding how different neurophysiological systems exacerbate or dampen the stress experience may help reveal why some people have more intense emotional responses to negative life events than others. The present findings affirm that the SNS and related adrenergic/noradrenergic systems help instantiate human affective experiences, while also expanding our mechanistic knowledge about the pathways linking stress and health.

References

1. Burger K, Samuel R. The role of perceived stress and self-efficacy in young people's life satisfaction: a longitudinal study. J Youth Adolesc 2017;46:78–90.
2. O'Donovan A, Tomiyama AJ, Lin J, Puterman E, Adler NE, Kemeny M, Wolkowitz OM, Blackburn EH, Epel ES. Stress appraisals and cellular aging: a key role for anticipatory threat in the relationship between psychological stress and telomere length. Brain Behav Immun 2012;26:573–9.
3. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull 2014;140:774–815.
4. McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci 2010;1186:190–222.
5. Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA 2007;298:1685–7.
6. Mathur MB, Epel E, Kind S, Desai M, Parks CG, Sandler DP, Khazeni N. Perceived stress and telomere length: a systematic review, meta-analysis, and methodologic considerations for advancing the field. Brain Behav Immun 2016;54:158–69.
7. Moore RC, Eyler LT, Mausbach BT, Zlatar ZZ, Thompson WK, Peavy G, Fazeli PL, Jeste DV. Complex interplay between health and successful aging: role of perceived stress, resilience, and social support. Am J Geriatr Psychiatry 2015;23:622–32.
8. Shavitt S, Cho YI, Johnson TP, Jiang D, Holbrook A, Stavrakantonaki M. Culture moderates the relation between perceived stress, social support, and mental and physical health. J Cross Cult Psychol 2016;47:956–80.
9. Steenen SA, van Wijk AJ, van der Heijden GJMG, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol 2016;30:128–39.
10. Srinivasan A. Propranolol: a 50-year historical perspective. Ann Indian Acad Neurol 2019;22:21–6.
11. Sterling P, Laughlin S. Principles of neural design. In: Principles of Neural Design. Cambridge, MA: MIT Press Books; 2015:1–542.
12. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm Behav 2003;43:2–15.
13. Berridge CW. Noradrenergic modulation of arousal. Brain Res Rev 2008;58:1–17.
14. Satpute AB, Kragel PA, Barrett LF, Wager TD, Bianciardi M. Deconstructing arousal into wakeful, autonomic and affective varieties. Neurosci Lett 2019;693:19–28.
15. Robbins TW, Everitt BJ. Arousal systems and attention. In: Gazzaniga MS, editor. The Cognitive Neurosciences. The MIT Press; 1995:703–20.
16. William Tank A, Lee Wong D. Peripheral and central effects of circulating catecholamines. Compr Physiol 2015;5:1–15.
17. Stiles GL, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev 1984;64:661–743.
18. Reznikoff GA, Manaker S, Rhodes CH, Winokur A, Rainbow TC. Localization and quantification of beta-adrenergic receptors in human brain. Neurology 1986;36:1067–73.
19. James W. What is an emotion? Mind 1884;34:188–205.
20. Schachter S, Singer J. Cognitive, social, and physiological determinants of emotional state. Psychol Rev 1962;69:379–99.
21. Barrett LF. The theory of constructed emotion: an active inference account of interoception and categorization. Soc Cogn Affect Neurosci 2017;12:1–23.
22. MacCormack JK, Lindquist KA. Bodily contributions to emotion: Schachter's legacy for a psychological constructionist view on emotion. Emot Rev 2017;9:36–45.
23. Tyrer PJ, Lader MH. Physiological and psychological effects of ±-propranolol, +-propranolol and diazepam in induced anxiety. Br J Clin Pharmacol 1974;1:379–85.
24. Drew P, Barnes J, Evans S. The effect of acute beta-adrenoceptor blockade on examination performance. Br J Clin Pharmacol 1985;19:783–6.
25. File S, Lister R. A comparison of the effects of lorazepam with those of propranolol on experimentally-induced anxiety and performance. Br J Clin Pharmacol 1985;19:445–51.
26. Krantz DS, Contrada RJ, LaRiccia PJ, Anderson JR, Durel LA, Dembroski TM, Weiss T. Effects of beta-adrenergic stimulation and blockade on cardiovascular reactivity, affect, and type A behavior. Psychosom Med 1987;49:146–58.
27. Currie D, Lewis R, McDevitt D, Nicholson A, Wright N. Central effects of beta-adrenoceptor antagonists. I-performance and subjective assessments of mood. Br J Clin Pharmacol 1988;26:121–8.

28. Dyck JB, Chung F. A comparison of propranolol and diazepam for preoperative anxiolysis. Can J Anaesth 1991;38:704–9.

29. Jakobsson J, Rane K, Ryberg G. Oral premedication one hour before minor gynaecological surgery—does it have any effect? Acta Anaesthesiol Scand 1995;39:359–63.

30. Head A, Kendall MJ, Ferner R, Eagles C. Acute effects of beta blockade and exercise on mood and anxiety. Br J Sports Med 1996;30:238–42.

31. Mealy K, Ngeh N, Gillen P, Fitzpatrick G, Keane FB, Tanner A. Propranolol reduces the anxiety associated with day case surgery. Eur J Surg 1996;162:11–4.

32. Elman MJ, Sugar J, Fiscella R, Deutsch TA, Noth J, Nyberg M, Packo K, Anderson RJ. The effect of propranolol versus placebo on resident surgical performance. Trans Am Ophthalmol Soc 1998;96:283–91; discussion 291-4.

33. Harmer CJ, Perrett DI, Cowen PJ, Goodwin GM. Administration of the beta-adrenoceptor blocker propranolol impairs the processing of facial expressions of sadness. Psychopharmacology (Berl) 2001;154:383–9.

34. Tyrer PJ, Lader MH. Response to propranolol and diazepam in somatic and psychic anxiety. Br Med J 1974;2:14–6.

35. Rogers RD, Lancaster M, Wakeley J, Bhagwagar Z. Effects of beta-adrenoceptor blockade on components of human decision-making. Psychopharmacology (Berl) 2004;172:157–64.

36. Alexander JK, Hillier A, Smith RM, Tivarus ME, Beversdorf DQ. Beta-adrenergic modulation of cognitive flexibility during stress. J Cogn Neurosci 2007;19:468–78.

37. Andrews J, Pruessner JC. The combined propranolol/TSST paradigm—a new method for psychoneuroendocrinology. PLoS One 2013;8:e57567.

38. Dreifus L, Engler H, Kissler J. Retrieval-induced forgetting under psychosocial stress: no reduction by delayed stress and beta-adrenergic blockade. Neurobiol Learn Mem 2014;110:35–46.

39. Ernst M, Lago T, Davis A, Grillon C. The effects of methylphenidate and propranolol on the interplay between induced-anxiety and working memory. Psychopharmacology (Berl) 2016;233:3565–74.

40. Ali N, Nitschke JP, Cooperman C, Pruessner JC. Suppressing the endocrine and autonomic stress systems does not impact the emotional stress experience after psychosocial stress. Psychoneuroendocrinology 2017;78:125–30.

41. Steptoe A, Ronaldson A, Kostich K, Lazzarino AI, Urbanova L, Carvalho LA. The effect of beta-adrenergic blockade on inflammatory and cardiovascular responses to acute mental stress. Brain Behav Immun 2018;70:369–75.

42. Hartley LR, Ungapen S, Davie I, Spencer DJ. The effect of beta adrenergic blocking drugs on speakers' performance and memory. Br J Psychiatry 1983;142:512–7.

43. Gottschalk LA, Stone WN, Gleser GC. Peripheral versus central mechanisms accounting for antianxiety effects of propranolol. Psychosom Med 1974;36:47–56.

44. Ashton H, Millman JE, Telford R, Thompson JW. A comparison of some physiological and psychological effects of propranolol and diazepam in normal subjects. Br J Clin Pharmacol 1976;3:551–9.

45. Nakano S, Gillespie HK, Hollister LE. Propranolol in experimentally induced stress. Psychopharmacology (Berl) 1978;59:279–84.

46. Landauer AA, Pocock DA, Prott FW. Effects of atenolol and propranolol on human performance and subjective feelings. Psychopharmacology (Berl) 1979;60:211–5.

47. Taylor EA, Harrison J, Turner P. Propranolol in experimentally induced stress. Br J Psychiatry 1981;139:545–9.

48. Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. Am J Med 1982;72:88–94.

49. Salem S, McDevitt D. Central effects of single oral doses of propranolol in man. Br J Clin Pharmacol 1984;17:31–6.

50. Stone WN, Gleser GC, Gottschalk LA. Anxiety and β-adrenergic blockade. Arch Gen Psychiatry 1973;29:620–2.

51. Blascovich J, Mendes WB. Social psychophysiology and embodiment. In: Fiske ST, Gilbert DT, Lindzey G, editors. The Handbook of Social Psychology. 5th ed. New York, NY: John Wiley & Sons, Inc.; 2010:194–227.

52. Lazarus RS, Folkman S. Stress, Appraisal, and Coping. New York: Springer; 1984.

53. Nater UM, Rohleder N. Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology 2009;34:486–96.

54. Nagy T, van Lien R, Willemsen G, Proctor G, Efting M, Fülöp M, Bárdos G, Veerman ECI, Bosch JA. A fluid response: alpha-amylase reactions to acute laboratory stress are related to sample timing and saliva flow rate. Biol Psychol 2015;109:111–9.

55. Achong MR, Piafsky KM, Ogilvie RI. Duration of cardiac effects of timolol and propranolol. Clin Pharmacol Ther 1976;19:148–52.

56. Harris WS, Schoenfeld CD, Weissler AM. Effects of adrenergic receptor activation and blockade on the systolic pre-ejection period, heart rate, and arterial pressure in man. J Clin Invest 1967;46:1704–14.

57. Hunt D, Sloman G, Clark RM, Hoffmann G. Effects of beta-adrenergic blockade on the systolic time intervals. Am J Med Sci 1970;259:97–113.

58. Benschop RJ, Nieuwenhuis EE, Tromp EA, Godaert GL, Ballieux RE, van Doornen LJ. Effects of beta-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. Circulation 1994;89:762–9.

59. Berntson GG, Cacioppo JT, Binkley PF, Uchino BN, Quigley KS, Fieldstone A. Autonomic cardiac control. III. Psychological stress and cardiac response in autonomic space as revealed by pharmacological blockades. Psychophysiology 1994;31:599–608.

60. Cacioppo JT, Berntson GG, Binkley PF, Quigley KS, Uchino BN, Fieldstone A. Autonomic cardiac control. II. Noninvasive indices and basal response as revealed by autonomic blockades. Psychophysiology 1994;31:586–98.

61. Kudielka BM, Fischer JE, Metzenthin P, Helfricht S, Preckel D, von Känel R. No effect of 5-day treatment with acetylsalicylic acid (aspirin) or the beta-blocker propranolol (inderal) on free cortisol responses to acute psychosocial stress: a randomized double-blind, placebo-controlled study. Neuropsychobiology 2007;56:159–66.

62. van Stegeren A, Rohleder N, Everaerd W, Wolf OT. Salivary alpha amylase as marker for adrenergic activity during stress: effect of betablockade. Psychoneuroendocrinology 2006;31:137–41.

63. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'—a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993;28:76–81.

64. Moors A, Ellsworth PC, Scherer KR, Frijda NH. Appraisal theories of emotion: state of the art and future development. Emot Rev 2013;5:119–24.

65. Williams FM, Leeser JE, Rawlins MD. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers. Br J Clin Pharmacol 1986;22:301–8.

66. MacCormack JK, Gaudier-Diaz MM, Armstrong-Carter EL, Arevalo JMG, Meltzer-Brody S, Sloan EK, Cole SW, Muscatell KA. Beta-adrenergic blockade blunts inflammatory and antiviral/antibody gene expression responses to acute social stress. Neuropsychopharmacology 2021;46:756–62.

67. MacCormack JK, Armstrong-Carter EL, Humphreys KL, Muscatell KA. Neurophysiological contributors to advantageous risk-taking: an experimental psychopharmacological investigation. Soc Cogn Affect Neurosci 2021;16:926–36.

68. Watson D, Clark LA. The PANAS-X: Manual for the Positive and Negative Affect Schedule—Expanded Form. Ames: University of Iowa; 1994.

69. Stevenson RA, Mikels JA, James TW. Characterization of the affective norms for english words by discrete emotional categories. Behav Res Methods 2007;39:1020–4.

70. Warriner AB, Kuperman V, Brysbaert M. Norms of valence, arousal, and dominance for 13,915 English lemmas. Behav Res Methods 2013;45:1191–207.

71. Tomaka J, Blascovich J, Kelsey RM, Leitten CL. Subjective, physiological, and behavioral effects of threat and challenge appraisal. J Pers Soc Psychol 1993;65:248–60.

72. Mendes WB, Blascovich J, Major B, Seery M. Challenge and threat responses during downward and upward social comparisons. Eur J Soc Psychol 2001;31:477–97.

73. Newlin DB, Levenson RW. Pre-ejection period: measuring beta-adrenergic influences upon the heart. Psychophysiology 1979;16:546–53.

74. Berntson GG, Cacioppo JT, Quigley KS. Respiratory sinus arrhythmia: autonomic origins, physiological mechanisms, and psychophysiological implications. Psychophysiology 1993;30:183–96.

75. de Geus EJC, Gianaros PJ, Brindle RC, Jennings JR, Berntson GG. Should heart rate variability be "corrected" for heart rate? Biological, quantitative, and interpretive considerations. Psychophysiology 2019;56:e13287.

76. Sokol-Hessner P, Lackovic SF, Tobe RH, Camerer CF, Leventhal BL, Phelps EA. Determinants of propranolol's selective effect on loss aversion. Psychol Sci 2015;26:1123–30.

77. Dedovic K, Wadiwalla M, Engert V, Pruessner JC. The role of sex and gender socialization in stress reactivity. Dev Psychol 2009;45:45–55.

78. Duchesne A, Pruessner JC. Association between subjective and cortisol stress response depends on the menstrual cycle phase. Psychoneuroendocrinology 2013;38:3155–9.

79. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw 2015;67:1–48.

80. Mazzuero G, Galdangelo F, Zotti AM, Bertolotti G, Tavazzi L. Effects of propranolol, atenolol, and chlordesmethildiazepam on response to mental stress in patients with recent myocardial infarction. Clin Cardiol 1987;10:293–302.

81. Armstrong C, Kapolowicz MR. A preliminary investigation on the effects of atenolol for treating symptoms of anxiety. Mil Med 2020;185:e1954–60.

82. Benjamin AB, Dooley TP. Anxiolytic benefits of compounded atenolol–scopolamine in eight patients in psychiatry. Pers Med Psychiatry 2020;19–20:100051.

83. Storbeck J, Clore GL. Affective arousal as information: how affective arousal influences judgments, learning, and memory. Soc Pers Psychol Compass 2008;2:1824–43.

84. MacCormack JK, Lindquist KA. Feeling hangry? When hunger is conceptualized as emotion. Emotion 2018;19:301–19.

85. Siemer M, Mauss I, Gross JJ. Same situation—different emotions: how appraisals shape our emotions. Emotion 2007;7:592–600.

86. Pitzalis MV, Mastropasqua F, Massari F, Passantino A, Totaro P, Forleo C, Rizzon P. β-Blocker effects on respiratory sinus arrhythmia and baroreflex gain in normal subjects. Chest 1998;114:185–91.

87. Park J, Bang H, Cañette I. Blinding in clinical trials, time to do it better. Complement Ther Med 2008;16:121–3.

88. Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 2005;144:317–22.